🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🆕article in press: Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study G Curigliano MD PhD doi.org/10.1016/j.anno…

🚨Hot off the press! 🌟 We're thrilled to announce the publication of our article in the ASCO Educational Handbook 👉"Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras." 🦓 just in time for AACR & ASCO meetings! Read it for FREE online now!

📢 #ESMOFellowship applications are now open! The Society is committed to supporting #YoungOncologists in developing high-quality #TranslationalResearch or #ClinicalResearch projects. 📅 Apply by: 29 May 2025 🔗 ow.ly/tz3e50VAQuM Evandro de Azambuja, MD, PhD Teresa Amaral, MD, PhD

A unique opportunity for youngers to boost and transform their career ESMO - Eur. Oncology @Teresa Amaral

Learn about #BrainMetastases prevalence by therapy line and incidence of #BreastCancerBrainMetastases in this just published cohort study in JNCI. 👉pubmed.ncbi.nlm.nih.gov/40163696/ Dr Sarah Sammons Timothy Erick, PhD Filippo Montemurro Sara Tolaney #JosePabloLeone Nancy Lin, MD

Leveraging real-world data to advance biomarker discovery and precision oncology dlvr.it/TKFKqv

📌 Prevalence by therapy line and incidence of breast cancer brain metastases in 18,075 patients academic.oup.com/jnci/advance-a… Dr Sarah Sammons Sara Tolaney Nancy Lin, MD Filippo Montemurro OncoAlert #OncoAlertAF 👉🏻 prevalence and cumulative incidence of brain metastases in a large MBC patient

Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity In this review in ESMO Open we address this topic👇🏻 OncoAlert sciencedirect.com/science/articl…

Cancer-associated Cachexia is a lethal metabolic syndrome marked by systemic inflammation, CNS appetite dysregulation, & muscle/fat loss—better characterized with imaging. Prevalent in cancers like pancreatic/lung, it's linked to IL-6, GDF-15, & tumor-driven energy drain. Trials

No biomarkers for ICI efficacy in early Tnbc Marleen Kok #ESMOAmbassadors #ESMOBreast25 ESMO - Eur. Oncology

🚨🥁Exciting Nature Medicine Publication Announcement 👉Hot off the press on this #ClinicalTrialsDay ! Thrilled to share our Nature Medicine paper: "Cancer treatment paradigms in the precision medicine era" 👉We propose 5 BOLD strategic recommendations to modernize cancer

Very important paper!

The curves everybody’s been waiting for. First line T-DXd + pertuzumab significantly prolonged PFS over THP for HER2+ MBC (40.7 vs 26.9 months, HR 0.56, p<0.001), doubled the rate of complete responses (15% vs 8%) and had a positive OS trend (HR 0.84). Practice changing data.

International effort 🇧🇪🇮🇹🇧🇷 for more evidence on RWD on the efficacy of APT regimen.

ADCs are rapidly improving the way we treat every type of cancer. Their potential has been largely unleashed over the past 6 years— yet their technology is the result of a 100-year long, epic journey. Join Raffaele Colombo & me to uncover 10 milestones in the development of ADCs (🧵):

Online Now: A unified pan-cancer proteome atlas dlvr.it/TLPtvc

Tumor-agnostic approvals by U.S. FDA The Oncologist Nakul Shah MD Anderson Cancer Center #precision #agnostic OncoAlert Oncology Brothers doi.org/10.1093/oncolo…

We look forward to receiving excellent clinical or translational study proposals from young colleagues! Matteo Lambertini, MD PhD Benjamin Besse Evandro de Azambuja, MD, PhD Antonio Marra ESOncology Organisation of European Cancer Institutes Università di Genova EORTC ESMO - Eur. Oncology IASLC OncoAlert

Diversity in clinical trials: Maghreb pts have younger age and more aggressive BC but similar survival outcomes doi.org/10.1016/j.clbc… Chiara Dauccia Véronique Debien Soraia Lobo-Martins Elisa Agostinetto Luca Arecco, MD Diogo Martins Branco

Extraordinary talk. One of the highlights of our program!